Primary Site >> Colorectal Cancer
Gene >> CDAN1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. PMID: 7545219 |
Ref: Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. PMID: 9815699 |
Ref: 5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules. PMID: 9932161 |
Ref: Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. PMID: 10080615 Ref: Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. PMID: 10506594 Ref: Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group. PMID: 10509152 |
Ref: ZD-9331 AstraZeneca. PMID: 11249590 |
Ref: Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial. PMID: 11331322 |
Ref: Multicenter phase I study of irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory advanced colorectal cancer. PMID: 12187070 Ref: Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies. PMID: 12393999 Ref: Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies. PMID: 12453855 |
Ref: A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer. PMID: 12881390 |
Ref: Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer. PMID: 15014354 Ref: Phase I study of UFT plus leucovorin with radiotherapy in patients with inextirpable non-rectal gastrointestinal cancer. PMID: 15028404 Ref: Phase I study of postoperative radiotherapy with concomitant weekly irinotecan, 5- fluorouracil and folinic acid in locally advanced rectal cancer. PMID: 17415823 Ref: The RACOX phase I study: radiation (RA), capecitabine (C) and oxaliplatin (OX) as adjuvant treatment of stage II and III rectal cancer. PMID: 17415843 |
Ref: Phase I study of concomitant chemoradiation with raltitrexed in locally advanced head and neck cancer. PMID: 15719490 Ref: Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours. PMID: 15913988 Ref: Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. PMID: 16301595 |
Ref: Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. PMID: 16446337 |
Ref: Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study. PMID: 17237473 |
Ref: Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. PMID: 18332469 Ref: [Phase I study of CPT-11 and continuous 5-FU / l-leucovorin combination therapy(modified AIO regimen)in patients with metastatic colorectal cancer]. PMID: 18931571 |
Ref: Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study. PMID: 19184020 |
Ref: Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. PMID: 20092990 Ref: Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. PMID: 20107803 Ref: Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). PMID: 20215798 Ref: A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. PMID: 20463088 Ref: Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. PMID: 21208844 |
Ref: Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement. PMID: 20941597 Ref: Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. PMID: 21976547 Ref: Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. PMID: 22027708 |
Ref: Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer. PMID: 21611734 Ref: A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy. PMID: 21863237 Ref: Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. PMID: 22674635 |
Ref: Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer. PMID: 23921573 Ref: A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. PMID: 24022191 |
Ref: Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients. PMID: 23568716 Ref: Negative-balance isolated pelvic perfusion in patients with incurable symptomatic rectal cancer: results and drug dose correlation to adverse events. PMID: 24097815 Ref: Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer. PMID: 25012517 |
Ref: A phase I trial of preoperative S-1 in combination with oxaliplatin and pelvic radiation for lower rectal cancer with T4 and lateral pelvic lymph node metastasis. PMID: 24839048 Ref: Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors. PMID: 25715763 Ref: Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer. PMID: 26163340 Ref: Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors. PMID: 26268924 |
Ref: Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer. PMID: 26632033 Ref: A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors. PMID: 26864210 Ref: Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. PMID: 27085994 |
Ref: Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. PMID: 28280091 Ref: Endorectal Brachytherapy Boost After External Beam Radiation Therapy in Elderly or Medically Inoperable Patients With Rectal Cancer: Primary Outcomes of the Phase 1 HERBERT Study. PMID: 28366579 Ref: First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. PMID: 28422758 Ref: [Safety and efficacy of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) in Chinese patients with advanced colorectal cancer]. PMID: 28535657 Ref: Genotype-driven phase I study of weekly irinotecan in combination with capecitabine-based neoadjuvant chemoradiation for locally advanced rectal cancer. PMID: 29273261 |
Ref: Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer. PMID: 29486916 Ref: Phase I study combining the aurora kinase a inhibitor alisertib with mFOLFOX in gastrointestinal cancer. PMID: 30191522 |